An interventional study of Transcranial Magnetic Stimulation in Mild Cognitive Impairment, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 60 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Duke University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Cognitive Dysfunction by Duke University — 4 open to participants now, 4 under way, none of them phase 3. Cognitive Dysfunction · Duke University.
Among the 20 studies in Cognitive Dysfunction by Duke University, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 11 with no phase, and was the 16th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →4 of the 20 studies in Cognitive Dysfunction by Duke University are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18–100
Duke University · Sites in United States, Puerto Rico
Ages 75+ · Healthy volunteers
Duke University · Sites in United States
Ages 25–80 · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 82 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 48 across the 14 interventional studies, 286 across the 6 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
3 of the studies in Cognitive Dysfunction by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04262206Duke UniversityPragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT05144516Duke UniversityCancer and Mild Cognitive Impairment Dyadic Intervention | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Cognitive Dysfunction by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed research will test a novel network-based neurostimulation approach using MRI-derived measures of brain connectivity to establish target sites for neurostimulation and test for the enhancement of memory function beyond a sham stimulation condition. This will be tested in cohort of MCI adults using network-based transcranial magnetic stimulation (TMS) to assess for behavioral improvement due to the controlled intervention. This study will provide important evidence towards the efficacy of neuromodulatory treatments for memory decline and will accelerate the discovery of potent non-invasive treatments to remediate cognitive decline in cognitively impaired older adults.
Dementia due to Alzheimer's disease (AD) is a leading public health concern in the US with tremendous care costs and no effective pharmacotherapy despite multiple clinical trials. Numerous studies have shown mild cognitive impairment (MCI) to be a precursor to AD and potentially amenable to nonpharmacological intervention. Transcranial magnetic stimulation (TMS) is a promising non-invasive therapeutic approach that has been shown to increase brain plasticity and enhance cognitive functions that are impaired across the AD spectrum. Yet, while TMS has shown benefits in normative populations, there is still a need to show efficacy in AD-related populations.
Most previous neurostimulation research on AD and MCI has focused on effects of stimulation at one brain region, however the cognitive processes underlying successful memory are mediated by a complex whole-brain network. Neurostimulation affects multiple sites within a cortical network, but these more global effects have not been used as targets for stimulation because of limited knowledge about what influence of a single site on more widespread cortical changes. The novelty of the current proposal is that the investigators use information about the network control structure of the affected brain areas by considering the influence of neuromodulation on global changes in brain state or connectivity and the underlying vascular changes mediating long-term consequences for behavior. This network-based TMS is informed by functional connectivity and neurovascular as mediators of the behavioral response as a means to specifically tailor the TMS treatment to the neuropathology of each MCI patient, thus individualizing the treatment to achieve better therapeutic effects.
To address this problem, the investigators will use multimodal neuroimaging and network modeling during an episodic memory task to demonstrate how focal neurostimulation evokes changes in neural function and behavior in MCI. These goals will be addressed in two specific aims. First, the investigators will use network-based TMS to optimize the activation of a memory success network (MSN) in a group of MCI patients, targeting a TMS site that focused on the controllability of a stimulation site to provide the maximum benefit to memory performance. Second, the study team will assess longitudinal change in structural and neurovascular factors affecting the efficacy of individualized network-based TMS across multiple sessions of concurrent TMS-fMRI. By creating a multimodal model of these neurovascular deficits related to MCI, the investigators will systematically adjust network-based TMS to demonstrate how the MCI brain might compensate for these neural deficits. The proposed work will be the first of its kind to estimate the utility of network controllability as a TMS target for memory enhancement in AD-related syndromes, and the first to assess the short-term neuroplastic effects of neuromodulation in such rich detail. The knowledge gained by this project may therefore lead to novel and innovative biometrics for gauging pharmacological and nonpharmacological treatment response or for targeted and enriched clinical trials in AD and related disorders.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study comprises one arm of five sessions. In Day 1 (\~1.5 hr session), participants fill forms, complete a neuropsychological test battery (NIH Toolbox, NACC UDS, BDI), and provide a saliva sample to be banked for future APOE genotype determination. On Day 2 (\~1 hr session), subjects will perform an initial MRI scanning session. In this session, MRI, RSFA, DWI, and fMRI are collected so they can be used for network-based targeting. In Days 3-5 (each comprising a \~2.5 hr session) a few days later participants will undergo combined TMS-fMRI sessions. In the scanner, participants complete four fMRI runs: 2 runs using either a network-based or standard target location, counterbalanced across participants. Active and Sham TMS trials are intermixed within each run.
Device: Transcranial Magnetic Stimulation
Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve a variety of cognitive conditions, and to probe the dynamics of normal brain function.
Also known as: TMS, rTMS
Episodic Memory Task Performance
The primary outcome measure is the difference in memory accuracy between TMS conditions (active vs. sham) on an episodic memory task. Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. During the Retrieval phase (post-scan), participants perform a recognition memory task including a mix of old objects and new objects, and memory is then subsequently assessed as a function of TMS condition. Reported as a hit rate, calculated by dividing the number of correct responses by the number of presented tasks.
Time frame: Baseline + Follow-up session, at day 3
Change in Representational Strength of Episodic Memories
The primary outcome measure is the difference in Representational Strength between TMS conditions (active vs. sham) during the episodic encoding task, at the site of TMS stimulation (Lateral Parietal Cortex). Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. Representational strength reflects the degree to which participants use semantic or perceptual information during encoding. Representational strength is calculated by comparing the similarity in activation patterns in a given brain region with the similarity in model estimates (semantic model: overlap of semantic features; perceptual model: overlap of perceptual features. As such, this measure reflects a Pearson's correlation (between -1 and 1) between brain and model similarity measures.
Time frame: Baseline + Follow-up session, at day 3
| Milestone | Network-guided TMS | Sham TMS |
|---|---|---|
| Started | 20 | 17 |
| Completed | 12 | 17 |
| Not completed | 8 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 |
| Withdrew: Withdrawal by pi | 3 | 0 |
The primary outcome measure is the difference in memory accuracy between TMS conditions (active vs. sham) on an episodic memory task. Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. During the Retrieval phase (post-scan), participants perform a recognition memory task including a mix of old objects and new objects, and memory is then subsequently assessed as a function of TMS condition. Reported as a hit rate, calculated by dividing the number of correct responses by the number of presented tasks.
| proportion of correct responses | Network-guided TMS | Sham TMS |
|---|---|---|
| Baseline | 0.64 ± 0.12 | 0.66 ± 0.16 |
| Follow-up Session | 0.78 ± 0.12 | 0.69 ± 0.08 |
The primary outcome measure is the difference in Representational Strength between TMS conditions (active vs. sham) during the episodic encoding task, at the site of TMS stimulation (Lateral Parietal Cortex). Participants perform the Episodic Memory task after active network-guided or sham TMS. During each block of the Encoding phase, participants view a series of real-world objects and perform a relatedness judgement. Representational strength reflects the degree to which participants use semantic or perceptual information during encoding. Representational strength is calculated by comparing the similarity in activation patterns in a given brain region with the similarity in model estimates (semantic model: overlap of semantic features; perceptual model: overlap of perceptual features. As such, this measure reflects a Pearson's correlation (between -1 and 1) between brain and model similarity measures.
| Correlation coefficient | Network-guided TMS | Sham TMS |
|---|---|---|
| Baseline | 0.018 ± 0.04 | 0.013 ± 0.04 |
| Follow-up Sessions | 0.029 ± 0.04 | 0.011 ± 0.04 |
Collected over Up to 72 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Network-guided TMS | 0/20 (0%) | 0/20 (0%) | 4/20 (20%) |
| Sham TMS | 0/17 (0%) | 0/17 (0%) | 0/17 (0%) |
| Event | Network-guided TMS | Sham TMS |
|---|---|---|
| Mood changesPsychiatric disorders | 1/20 | 0/17 |
| NeuralgiaNervous system disorders | 1/20 | 0/17 |
| Incidental finding during fMRINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/20 | 0/17 |
| HeadacheNervous system disorders | 1/20 | 0/17 |
| Age, Continuous(years) | Network-guided TMS | Sham TMS | Total |
|---|---|---|---|
| Mean | 72.6 ± 5.6 | 73.3 ± 3.3 | 72.9 ± 4.7 |
| Sex: Female, Male(Participants) | Network-guided TMS | Sham TMS | Total |
|---|---|---|---|
| Female | 15 | 8 | 23 |
| Male | 5 | 9 | 14 |
| Race (NIH/OMB)(Participants) | Network-guided TMS | Sham TMS | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 18 | 15 | 33 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Network-guided TMS | Sham TMS | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 18 | 17 | 35 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Network-guided TMS | Sham TMS | Total |
|---|---|---|---|
| United States | 20 | 17 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in Jun 2025, 39 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 39 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.